Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 91,700 shares, a decline of 33.8% from the November 30th total of 138,600 shares. Based on an average trading volume of 2,921,900 shares, the days-to-cover ratio is presently 0.0 days.

Bayer Aktiengesellschaft Stock Up 2.5 %

Shares of OTCMKTS:BAYRY traded up $0.12 during trading on Friday, hitting $4.97. The company’s stock had a trading volume of 2,492,553 shares, compared to its average volume of 1,446,597. Bayer Aktiengesellschaft has a fifty-two week low of $4.79 and a fifty-two week high of $9.79. The stock’s 50-day moving average price is $5.66 and its two-hundred day moving average price is $6.85. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. The company has a market capitalization of $19.53 billion, a PE ratio of -19.12 and a beta of 1.03.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.10). The firm had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. As a group, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat, Bayer Aktiengesellschaft presently has an average rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.